































	 Simple	 and	 precise	 spectrofluorometric	 method	 has	 been	 developed	 and	 validated	 for	 the
determination	of	linagliptin	(LNG)	in	the	range	of	10‐110	μg/mL.	The	results	obtained	were	of
good	precision	and	statistically	compared	to	the	reference	method	using	one‐way	analysis	of
variance	 (ANOVA).	 The	 method	 developed	 was	 satisfactorily	 applied	 to	 the	 analysis	 of	 the
pharmaceutical	formulation	and	proved	to	be	specific	and	accurate	for	the	quality	control	of













1H‐purine‐2,6‐dione]	 (Figure	 1)	 is	 a	 new	 hypoglycemic	 drug	
that	 belongs	 to	 dipeptidyl‐peptidase‐4	 inhibitor	 class	 which	
stimulates	 glucose‐dependent	 insulin	 release	 [1,2].	 DPP‐4	
inhibitors	 represent	 a	 new	 therapeutic	 approach	 to	 the	
treatment	 of	 type	 2	 diabetes	 that	 functions	 to	 stimulate	
glucose‐dependent	insulin	release	and	reduce	glucagons	levels.	
This	is	done	through	inhibition	of	the	inactivation	of	 incretins,	
particularly	 glucagon‐like	 peptide‐1	 (GLP‐1)	 and	 gastric	
inhibitory	 polypeptide	 (GIP)	 [1,2].	Only	 one	method	has	 been	







The	 aim	 of	 the	 present	 work	 was	 to	 develop	 a	
spectrofluorometric	 method	 for	 the	 determination	 of	 LNG	
based	 on	 the	 native	 fluorescence	 of	 the	 drug.	 Spectro‐
fluorometry	 has	 long	 been	 applied	 in	 the	 field	 of	
pharmaceutical	 analysis	 of	 many	 drugs	 [4‐7]	 because	 of	 the	
higher	 sensitivity	 than	 is	 attainable	 in	 absorption	 spectro‐
photometry.	A	necessary	condition	for	a	compound	to	fluoresce	
is	 that	 it	 absorbs	 light	 in	 the	 UV	 or	 visible	 region	 of	 the	
spectrum.	 Accordingly,	 compounds	 that	 have	 a	 conjugated	 π‐
electron	system	may	give	efficient	re‐emission	of	the	absorbed	






















































by	 dissolving	 100	 mg	 of	 the	 drug	 in	 acetonitrile:methanol,	
(90:10,	 v:v)	 and	 completing	 the	 volume	 to	 100	 mL	 in	 a	
volumetric	 flask	 and	 then	 the	 required	 concentrations	 were	





Aliquots	 from	 LNG	 stock	 standard	 solution	 equivalent	 to	
100‐1100	μg	were	accurately	measured	and	transferred	into	a	
set	of	10	mL	volumetric	flasks	and	the	volumes	were	completed	
with	 acetonitrile:methanol,	 (90:10,	 v:v).	 The	 relative	
fluorescence	intensity	was	measured	at	the	specified	excitation	
and	emission	wavelengths	 (λem	at	435	nm	with	λex	at	339	nm	





The	 relative	 fluorescence	 intensity	 of	 LNG	 in	 bulk	 was	
measured	at	the	specified	excitation	and	emission	wavelengths	







An	accurately	weighed	amount	of	 the	 finely	powdered	 tablets	
equivalent	 to	 100	mg	 of	 LNG	were	made	 up	 to	 100	mL	with	
acetonitrile:methanol,	 (90:10,	 v:v),	 the	 solution	 was	 filtered	
followed	by	 serial	 dilution	 to	 the	 required	 concentration.	 The	





Literature	 survey	 reveals	 that	 only	 one	method	 has	 been	
described	 for	 the	 determination	 of	 LNG	 in	 its	 pharmaceutical	






Standard	 calibration	 curves	 were	 prepared	 by	 separately	
preparing	 series	 of	 different	 concentrations	 and	 applying	 the	
suggested	 procedures.	 The	 linearity	 of	 the	 calibration	 curve	
was	validated	by	 the	high	value	of	correlation	coefficient.	The	
analytical	 data	 of	 the	 calibration	 curve	 including	 standard	





bulk	 and	 determination	 of	 the	 concentrations	 in	 tablets.	 The	
results	 obtained	 were	 of	 good	 accuracy	 and	 precision.	 The	
applicability	 of	 the	 procedure	 for	 estimation	 of	 tablets	 was	







A	 statistical	 analysis	 of	 the	 results	 obtained	 by	 the	
proposed	method	for	the	determination	of	LNG	was	carried	out	









The	 proposed	 method	 has	 the	 advantages	 of	 simplicity,	
precision,	 accuracy	 and	 convenience	 for	 the	 quantitation	 of	
LNG.	The	proposed	method	can	be	used	for	the	quality	control	
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